PLX Protalix BioTherapeutics Inc. Return on Gross Profit

PLX (Protalix) - company brandmark

Israeli developer Protalix BioTherapeutics is feeling the impact of local instability in the Middle East, although the humanitarian status of its medications supports the business. Industry risks include the vulnerability of raw material supply chains and challenges with foreign certification. The gross margin ratio clearly demonstrates pricing power, with the indicator standing at 71.20. Protalix BioTherapeutics is focusing on the commercialization of therapies for rare pathologies, utilizing its innovative ProCellEx platform to reduce protein synthesis costs.

Protalix BioTherapeutics, Inc (PLX) Gross Profitability: for the period 07/04/2022 - 11/19/2026

Analytical breakdowns and data insights for company Protalix BioTherapeutics Inc. (PLX)

Summary company analysis:Protalix BioTherapeutics, Inc. - PLX
Manufactured products of Protalix BioTherapeutics, Inc.

Gross margin determines the share of profit after deducting direct production costs, serving as a key indicator of the issuer's operational efficiency and pricing power. By analyzing gross margin volatility, an investor assesses the ability of Protalix BioTherapeutics (PLX) to monetize its unique developments in plant-based protein expression, which confirms the high value of breakthrough enzyme therapies for treating rare genetic pathologies.